NASDAQ:PTX - Pernix Therapeutics Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$2.55 +0.08 (+3.24 %)
(As of 07/20/2018 04:00 PM ET)
Previous Close$2.47
Today's Range$2.48 - $2.58
52-Week Range$2.00 - $4.54
Volume53,000 shs
Average Volume94,704 shs
Market Capitalization$28.85 million
P/E RatioN/A
Dividend YieldN/A
Beta1.63
Pernix Therapeutics logoPernix Therapeutics Holdings, Inc., a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription drugs primarily for the United States market. It targets underserved therapeutic areas, such as central nervous system (CNS), including pain, neurology, and psychiatry. The company's products comprise Zohydro ER with BeadTek, an opioid agonist indicated for the management of pain; Silenor, a non-narcotic, non-scheduled, and non-addictive prescription sleep aid for the treatment of insomnia characterized by difficulty with sleep maintenance; and Treximet, a fixed dose combination product indicated for the treatment of acute migraine. Pernix Therapeutics Holdings, Inc. markets and sells its non-core products, including generics through its wholly owned subsidiaries; and markets its non-promoted products through distributors and trade partners. It serves drug wholesalers, specialty pharmacies, retail drug stores, mass merchandisers, and grocery store pharmacies. Pernix Therapeutics Holdings, Inc. was founded in 1996 and is headquartered in Morristown, New Jersey.

Receive PTX News and Ratings via Email

Sign-up to receive the latest news and ratings for PTX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
SymbolNASDAQ:PTX
CUSIP71426V10
Phone800-793-2145

Debt

Debt-to-Equity Ratio-1.45
Current Ratio0.88
Quick Ratio0.82

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$146.07 million
Price / Sales0.21
Cash FlowN/A
Price / CashN/A
Book Value($14.77) per share
Price / Book-0.17

Profitability

EPS (Most Recent Fiscal Year)N/A
Net Income$-77,140,000.00
Net Margins-45.87%
Return on EquityN/A
Return on Assets-37.89%

Miscellaneous

Employees171
Outstanding Shares11,870,000
Market Cap$28.85

Pernix Therapeutics (NASDAQ:PTX) Frequently Asked Questions

What is Pernix Therapeutics' stock symbol?

Pernix Therapeutics trades on the NASDAQ under the ticker symbol "PTX."

How were Pernix Therapeutics' earnings last quarter?

Pernix Therapeutics Holdings Inc (NASDAQ:PTX) announced its quarterly earnings data on Thursday, May, 10th. The specialty pharmaceutical company reported ($1.57) earnings per share (EPS) for the quarter. The specialty pharmaceutical company earned $28.14 million during the quarter. View Pernix Therapeutics' Earnings History.

When is Pernix Therapeutics' next earnings date?

Pernix Therapeutics is scheduled to release their next quarterly earnings announcement on Wednesday, July, 25th 2018. View Earnings Estimates for Pernix Therapeutics.

What is the consensus analysts' recommendation for Pernix Therapeutics?

0 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Pernix Therapeutics in the last year. There are currently for the stock, resulting in a consensus recommendation of "N/A."

Who are some of Pernix Therapeutics' key competitors?

Who are Pernix Therapeutics' key executives?

Pernix Therapeutics' management team includes the folowing people:
  • Mr. John Anthony Sedor, Chairman & CEO (Age 73)
  • Mr. Kenneth R. Pina Esq., Sr. VP, Chief Legal & Compliance Officer and Corp. Sec. (Age 59)
  • Mr. Angus W. Smith, Sr. VP, Chief Bus. Officer & Principal Financial Officer (Age 35)
  • Mr. Glenn Whaley, Principal Accounting Officer, VP of Fin. & Corp. Controller (Age 50)
  • Mr. Anthony M. Orrico, VP of Technical & Supply Operations

Has Pernix Therapeutics been receiving favorable news coverage?

News articles about PTX stock have been trending positive this week, Accern reports. Accern scores the sentiment of media coverage by reviewing more than 20 million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Pernix Therapeutics earned a media sentiment score of 0.27 on Accern's scale. They also assigned headlines about the specialty pharmaceutical company an impact score of 47.02 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company's share price in the next few days.

How do I buy shares of Pernix Therapeutics?

Shares of PTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Pernix Therapeutics' stock price today?

One share of PTX stock can currently be purchased for approximately $2.55.

How big of a company is Pernix Therapeutics?

Pernix Therapeutics has a market capitalization of $28.85 million and generates $146.07 million in revenue each year. Pernix Therapeutics employs 171 workers across the globe.

How can I contact Pernix Therapeutics?

Pernix Therapeutics' mailing address is 10 NORTH PARK PLACE SUITE 201, MORRISTOWN NJ, 07960. The specialty pharmaceutical company can be reached via phone at 800-793-2145 or via email at [email protected]


MarketBeat Community Rating for Pernix Therapeutics (NASDAQ PTX)

Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  289 (Vote Outperform)
Underperform Votes:  187 (Vote Underperform)
Total Votes:  476
MarketBeat's community ratings are surveys of what our community members think about Pernix Therapeutics and other stocks. Vote "Outperform" if you believe PTX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PTX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 7/20/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.